Humabody Drug Conjugates: A Novel Therapeutic Approach
This biopharma animation produced by our agency explains the advantages and biology behind Humabody Drug Conjugates (HDCs) as a cancer therapeutic.
Our client is leveraging Humabody Drug Conjugates (HDCs) to enhance antibody drug conjugates' potential. HDCs carry a potent toxin in a smaller size compared to traditional antibodies, leading to better tumor penetration and reduced systemic circulation.
The modular design of HDCs allows for multispecific formats, enhancing cancer cell targeting by binding to multiple targets simultaneously. This design also improves toxin internalization, potentially increasing efficacy while lowering toxicity.
HDCs offer a superior therapeutic index, allowing for a more aggressive treatment approach with maximum tumor impact and minimal systemic effects.
🧬 About Biotech Animated
For Scientists by Scientists. Biotech Animated is a life-science biomedical animation agency specialized in attracting investor funding and increasing B2B sales in the biotech and pharma industry.
Learn more about our work: https://www.biotech-animated.com